BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26400846)

  • 1. Paired-like Homeodomain Transcription factor 2 expression by breast cancer bone marrow disseminated tumor cells is associated with early recurrent disease development.
    Pillai SG; Dasgupta N; Siddappa CM; Watson MA; Fleming T; Trinkaus K; Aft R
    Breast Cancer Res Treat; 2015 Oct; 153(3):507-17. PubMed ID: 26400846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients.
    Watson MA; Ylagan LR; Trinkaus KM; Gillanders WE; Naughton MJ; Weilbaecher KN; Fleming TP; Aft RL
    Clin Cancer Res; 2007 Sep; 13(17):5001-9. PubMed ID: 17785550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients.
    Tjensvoll K; Oltedal S; Farmen RK; Shammas FV; Heikkilä R; Kvaløy JT; Gilje B; Smaaland R; Nordgård O
    Clin Breast Cancer; 2010 Oct; 10(5):378-84. PubMed ID: 20920982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells.
    Werner S; Stamm H; Pandjaitan M; Kemming D; Brors B; Pantel K; Wikman H
    BMC Cancer; 2015 Nov; 15():896. PubMed ID: 26560478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
    Pillai SG; Li S; Siddappa CM; Ellis MJ; Watson MA; Aft R
    Breast Cancer Res; 2018 Jan; 20(1):2. PubMed ID: 29291741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
    Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
    Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease.
    Siddappa CM; Watson MA; Pillai SG; Trinkaus K; Fleming T; Aft R
    Breast Cancer Res Treat; 2013 Jan; 137(1):45-56. PubMed ID: 23129172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
    Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker HF; Hiddemann W; Wulf GG
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):277-80. PubMed ID: 14518259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse.
    Siddappa CM; Pillai SG; Snider J; Alldredge P; Trinkaus K; Watson MA; Aft R
    Breast Cancer Res Treat; 2019 Nov; 178(2):317-325. PubMed ID: 31432366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasion of ovarian cancer cells is induced byPITX2-mediated activation of TGF-β and Activin-A.
    Basu M; Bhattacharya R; Ray U; Mukhopadhyay S; Chatterjee U; Roy SS
    Mol Cancer; 2015 Aug; 14():162. PubMed ID: 26298390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PITX2: a promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma.
    Zhang JX; Tong ZT; Yang L; Wang F; Chai HP; Zhang F; Xie MR; Zhang AL; Wu LM; Hong H; Yin L; Wang H; Wang HY; Zhao Y
    Int J Cancer; 2013 Jun; 132(11):2567-77. PubMed ID: 23132660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome.
    Tjensvoll K; Oltedal S; Heikkilä R; Kvaløy JT; Gilje B; Reuben JM; Smaaland R; Nordgård O
    BMC Cancer; 2012 May; 12():190. PubMed ID: 22640166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of PITX2 transcription factor contributes to ovarian cancer progression.
    Fung FK; Chan DW; Liu VW; Leung TH; Cheung AN; Ngan HY
    PLoS One; 2012; 7(5):e37076. PubMed ID: 22615897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients.
    Göbel G; Auer D; Gaugg I; Schneitter A; Lesche R; Müller-Holzner E; Marth C; Daxenbichler G
    Breast Cancer Res Treat; 2011 Nov; 130(1):109-17. PubMed ID: 21221769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
    Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M
    Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
    Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
    Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
    Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
    Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231.
    Morini M; Astigiano S; Gitton Y; Emionite L; Mirisola V; Levi G; Barbieri O
    BMC Cancer; 2010 Nov; 10():649. PubMed ID: 21108812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of β-catenin and paired-like homeobox 2B (PHOX2B) expression in neuroblastoma patients; predictive and prognostic value.
    El-Shazly SS; Hassan NM; Abdellateif MS; El Taweel MA; Abd-Elwahab N; Ebeid EN
    Exp Mol Pathol; 2019 Oct; 110():104272. PubMed ID: 31220430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.